| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anesthesiology | 7 | 2025 | 99 | 3.100 |
Why?
|
| Anesthesiologists | 3 | 2025 | 39 | 1.690 |
Why?
|
| Wearable Electronic Devices | 5 | 2022 | 108 | 1.590 |
Why?
|
| Anesthesia | 4 | 2017 | 212 | 1.540 |
Why?
|
| Physicians, Women | 2 | 2025 | 52 | 1.510 |
Why?
|
| History, 20th Century | 8 | 2025 | 396 | 1.040 |
Why?
|
| Fractional Flow Reserve, Myocardial | 6 | 2025 | 55 | 1.010 |
Why?
|
| Research Design | 5 | 2023 | 757 | 0.980 |
Why?
|
| Anti-Retroviral Agents | 2 | 2019 | 152 | 0.970 |
Why?
|
| Postmenopause | 9 | 2019 | 155 | 0.950 |
Why?
|
| Medicine | 2 | 2023 | 106 | 0.870 |
Why?
|
| Cardiovascular Diseases | 8 | 2023 | 2092 | 0.860 |
Why?
|
| Career Choice | 1 | 2025 | 163 | 0.830 |
Why?
|
| Students, Medical | 2 | 2018 | 364 | 0.810 |
Why?
|
| Faculty, Medical | 2 | 2018 | 281 | 0.770 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2025 | 303 | 0.770 |
Why?
|
| Weight Reduction Programs | 2 | 2021 | 60 | 0.770 |
Why?
|
| History, 19th Century | 6 | 2020 | 117 | 0.760 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2022 | 27 | 0.750 |
Why?
|
| Dermatitis, Atopic | 1 | 2022 | 46 | 0.740 |
Why?
|
| Societies, Medical | 1 | 2025 | 779 | 0.670 |
Why?
|
| Schools, Medical | 2 | 2020 | 124 | 0.660 |
Why?
|
| Humans | 94 | 2025 | 133181 | 0.650 |
Why?
|
| Transplantation, Heterologous | 1 | 2020 | 276 | 0.640 |
Why?
|
| United States | 23 | 2025 | 11711 | 0.620 |
Why?
|
| Coronary Artery Disease | 6 | 2025 | 895 | 0.610 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 562 | 0.600 |
Why?
|
| Sepsis | 5 | 2024 | 522 | 0.600 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 295 | 0.600 |
Why?
|
| Succinylcholine | 1 | 2018 | 4 | 0.590 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 2018 | 6 | 0.590 |
Why?
|
| Blood Transfusion | 1 | 2020 | 296 | 0.570 |
Why?
|
| Coronary Artery Bypass | 6 | 2025 | 535 | 0.570 |
Why?
|
| Philosophy | 1 | 2017 | 12 | 0.560 |
Why?
|
| Nitrous Oxide | 1 | 2017 | 13 | 0.560 |
Why?
|
| Hippocratic Oath | 1 | 2017 | 5 | 0.560 |
Why?
|
| Anesthesia, Dental | 1 | 2017 | 8 | 0.550 |
Why?
|
| Pediatric Obesity | 2 | 2021 | 413 | 0.550 |
Why?
|
| Psychology | 1 | 2017 | 60 | 0.550 |
Why?
|
| Halothane | 1 | 2017 | 11 | 0.550 |
Why?
|
| Religion | 1 | 2017 | 51 | 0.540 |
Why?
|
| Models, Statistical | 2 | 2020 | 499 | 0.540 |
Why?
|
| Patient Positioning | 1 | 2017 | 57 | 0.540 |
Why?
|
| Atrial Fibrillation | 5 | 2024 | 699 | 0.530 |
Why?
|
| Women's Health | 11 | 2017 | 150 | 0.530 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2014 | 313 | 0.530 |
Why?
|
| HIV Infections | 3 | 2021 | 2060 | 0.530 |
Why?
|
| Anesthetics, Inhalation | 1 | 2017 | 46 | 0.530 |
Why?
|
| Pandemics | 2 | 2024 | 1192 | 0.530 |
Why?
|
| California | 7 | 2025 | 144 | 0.520 |
Why?
|
| Anesthetics | 1 | 2017 | 78 | 0.520 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1156 | 0.520 |
Why?
|
| Peanut Hypersensitivity | 3 | 2023 | 84 | 0.520 |
Why?
|
| Anesthesia, Conduction | 1 | 2016 | 20 | 0.500 |
Why?
|
| Physicians | 1 | 2023 | 640 | 0.500 |
Why?
|
| Melanoma | 5 | 2015 | 953 | 0.500 |
Why?
|
| Middle Aged | 46 | 2025 | 28912 | 0.490 |
Why?
|
| Aspirin | 3 | 2014 | 231 | 0.480 |
Why?
|
| Pediatricians | 1 | 2016 | 71 | 0.470 |
Why?
|
| Teaching | 2 | 2014 | 201 | 0.470 |
Why?
|
| Anti-HIV Agents | 2 | 2021 | 350 | 0.460 |
Why?
|
| Female | 56 | 2025 | 71395 | 0.450 |
Why?
|
| Intensive Care Units | 2 | 2019 | 539 | 0.450 |
Why?
|
| Aged | 40 | 2025 | 21448 | 0.450 |
Why?
|
| Mobile Applications | 3 | 2021 | 108 | 0.430 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 361 | 0.430 |
Why?
|
| Academic Medical Centers | 3 | 2023 | 335 | 0.430 |
Why?
|
| Wine | 1 | 2013 | 15 | 0.420 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 2751 | 0.420 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2013 | 31 | 0.420 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 723 | 0.420 |
Why?
|
| Veterans | 5 | 2019 | 1782 | 0.420 |
Why?
|
| Skin Neoplasms | 7 | 2016 | 893 | 0.420 |
Why?
|
| Education, Medical | 1 | 2017 | 306 | 0.410 |
Why?
|
| Longitudinal Studies | 8 | 2024 | 1514 | 0.410 |
Why?
|
| Stroke | 4 | 2024 | 1079 | 0.410 |
Why?
|
| Radiation Oncology | 1 | 2013 | 28 | 0.400 |
Why?
|
| Hip Fractures | 1 | 2013 | 74 | 0.390 |
Why?
|
| Electric Stimulation Therapy | 1 | 2013 | 86 | 0.380 |
Why?
|
| Exercise | 7 | 2023 | 873 | 0.360 |
Why?
|
| Radiology | 1 | 2013 | 126 | 0.360 |
Why?
|
| Incidence | 13 | 2024 | 3385 | 0.340 |
Why?
|
| Adult | 26 | 2024 | 31616 | 0.340 |
Why?
|
| Proportional Hazards Models | 10 | 2019 | 1468 | 0.330 |
Why?
|
| Myocardial Infarction | 4 | 2025 | 1068 | 0.330 |
Why?
|
| Male | 36 | 2025 | 65478 | 0.330 |
Why?
|
| Outpatients | 5 | 2023 | 275 | 0.320 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 135 | 0.310 |
Why?
|
| Internship and Residency | 3 | 2020 | 1252 | 0.310 |
Why?
|
| Coronary Stenosis | 2 | 2021 | 81 | 0.300 |
Why?
|
| Cohort Studies | 14 | 2021 | 5191 | 0.280 |
Why?
|
| Asthma | 3 | 2021 | 807 | 0.280 |
Why?
|
| Prospective Studies | 14 | 2022 | 6571 | 0.270 |
Why?
|
| Diet, Fat-Restricted | 2 | 2018 | 40 | 0.270 |
Why?
|
| Diet, Carbohydrate-Restricted | 2 | 2018 | 28 | 0.270 |
Why?
|
| Diet, Reducing | 2 | 2018 | 94 | 0.260 |
Why?
|
| Risk Factors | 15 | 2024 | 10935 | 0.260 |
Why?
|
| Ischemic Attack, Transient | 2 | 2024 | 66 | 0.250 |
Why?
|
| Sleep Wake Disorders | 3 | 2025 | 188 | 0.240 |
Why?
|
| Primary Health Care | 2 | 2025 | 804 | 0.240 |
Why?
|
| Telemedicine | 3 | 2021 | 508 | 0.240 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2016 | 67 | 0.240 |
Why?
|
| Electrocardiography | 2 | 2021 | 997 | 0.230 |
Why?
|
| Vitamin D | 3 | 2016 | 180 | 0.230 |
Why?
|
| Menopause | 2 | 2015 | 90 | 0.220 |
Why?
|
| Telomere | 2 | 2016 | 227 | 0.220 |
Why?
|
| Ritonavir | 1 | 2024 | 46 | 0.220 |
Why?
|
| Sleep | 2 | 2025 | 370 | 0.220 |
Why?
|
| Desensitization, Immunologic | 3 | 2022 | 107 | 0.220 |
Why?
|
| Overweight | 4 | 2021 | 386 | 0.220 |
Why?
|
| Basophil Degranulation Test | 1 | 2023 | 1 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 1212 | 0.210 |
Why?
|
| History, 21st Century | 1 | 2025 | 276 | 0.210 |
Why?
|
| Heart Transplantation | 2 | 2023 | 887 | 0.200 |
Why?
|
| Pyridines | 2 | 2022 | 250 | 0.200 |
Why?
|
| Registries | 3 | 2019 | 1582 | 0.200 |
Why?
|
| Causality | 1 | 2023 | 94 | 0.200 |
Why?
|
| Circadian Rhythm | 1 | 2025 | 298 | 0.200 |
Why?
|
| Sports | 2 | 2021 | 67 | 0.190 |
Why?
|
| Coronary Vessels | 2 | 2017 | 540 | 0.190 |
Why?
|
| Antiviral Agents | 3 | 2024 | 823 | 0.190 |
Why?
|
| Machine Learning | 2 | 2025 | 345 | 0.190 |
Why?
|
| Cells | 1 | 2021 | 25 | 0.180 |
Why?
|
| Smoking | 3 | 2016 | 943 | 0.180 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 1558 | 0.180 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 3985 | 0.180 |
Why?
|
| Body Mass Index | 2 | 2021 | 1710 | 0.180 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2021 | 2 | 0.180 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 1602 | 0.180 |
Why?
|
| Renal Dialysis | 2 | 2018 | 892 | 0.180 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 36 | 0.170 |
Why?
|
| Coronary Angiography | 3 | 2025 | 484 | 0.170 |
Why?
|
| Piperazines | 1 | 2022 | 256 | 0.170 |
Why?
|
| Community Participation | 1 | 2021 | 42 | 0.170 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2021 | 77 | 0.170 |
Why?
|
| Logistic Models | 6 | 2016 | 1861 | 0.170 |
Why?
|
| Endpoint Determination | 1 | 2021 | 59 | 0.170 |
Why?
|
| Arachis | 4 | 2023 | 83 | 0.170 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2020 | 13 | 0.170 |
Why?
|
| History, 15th Century | 1 | 2020 | 14 | 0.170 |
Why?
|
| Leadership | 1 | 2023 | 247 | 0.170 |
Why?
|
| History, 17th Century | 1 | 2020 | 35 | 0.170 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2020 | 17 | 0.170 |
Why?
|
| History, Ancient | 1 | 2020 | 56 | 0.170 |
Why?
|
| Troponin I | 1 | 2021 | 121 | 0.170 |
Why?
|
| Fontan Procedure | 1 | 2023 | 191 | 0.170 |
Why?
|
| Boston | 1 | 2020 | 122 | 0.170 |
Why?
|
| Computer Simulation | 2 | 2024 | 708 | 0.170 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2020 | 715 | 0.160 |
Why?
|
| Interleukins | 1 | 2021 | 130 | 0.160 |
Why?
|
| Life Expectancy | 1 | 2020 | 60 | 0.160 |
Why?
|
| Air Pollution | 1 | 2021 | 75 | 0.160 |
Why?
|
| Patient Care Planning | 1 | 2021 | 130 | 0.160 |
Why?
|
| Sexism | 1 | 2020 | 43 | 0.160 |
Why?
|
| Mental Health | 2 | 2020 | 377 | 0.160 |
Why?
|
| Social Class | 1 | 2021 | 207 | 0.160 |
Why?
|
| Hospitalization | 3 | 2024 | 1910 | 0.160 |
Why?
|
| Weight Loss | 2 | 2021 | 516 | 0.160 |
Why?
|
| CpG Islands | 1 | 2021 | 347 | 0.160 |
Why?
|
| Workplace | 1 | 2020 | 82 | 0.160 |
Why?
|
| Polyethylene Glycols | 1 | 2021 | 254 | 0.160 |
Why?
|
| Telomere Homeostasis | 2 | 2016 | 46 | 0.150 |
Why?
|
| Treatment Outcome | 7 | 2025 | 13094 | 0.150 |
Why?
|
| Tachycardia, Ventricular | 1 | 2021 | 207 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 251 | 0.150 |
Why?
|
| Interleukin-18 | 1 | 2019 | 68 | 0.150 |
Why?
|
| Telomere Shortening | 2 | 2016 | 36 | 0.150 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 76 | 0.150 |
Why?
|
| Social Dominance | 1 | 2018 | 11 | 0.150 |
Why?
|
| Receptors, Estrogen | 1 | 2022 | 829 | 0.150 |
Why?
|
| Survivors | 1 | 2021 | 358 | 0.150 |
Why?
|
| Low Back Pain | 1 | 2019 | 40 | 0.150 |
Why?
|
| Pulmonary Alveoli | 1 | 2019 | 142 | 0.150 |
Why?
|
| Malignant Hyperthermia | 1 | 2018 | 19 | 0.150 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 7137 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2018 | 801 | 0.150 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2018 | 62 | 0.150 |
Why?
|
| Heart Rate | 1 | 2021 | 586 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 239 | 0.150 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2018 | 32 | 0.150 |
Why?
|
| Prevalence | 2 | 2022 | 2627 | 0.150 |
Why?
|
| Spasm | 1 | 2018 | 47 | 0.150 |
Why?
|
| Drug Industry | 1 | 2018 | 49 | 0.150 |
Why?
|
| Atrial Flutter | 1 | 2018 | 34 | 0.150 |
Why?
|
| Smartphone | 1 | 2018 | 45 | 0.150 |
Why?
|
| Calcium, Dietary | 2 | 2015 | 38 | 0.140 |
Why?
|
| Drug Approval | 1 | 2018 | 45 | 0.140 |
Why?
|
| Weight Gain | 1 | 2021 | 412 | 0.140 |
Why?
|
| Retrospective Studies | 10 | 2023 | 17526 | 0.140 |
Why?
|
| Vitamins | 2 | 2016 | 113 | 0.140 |
Why?
|
| Patient Safety | 2 | 2020 | 436 | 0.140 |
Why?
|
| Cardiac Catheters | 1 | 2017 | 10 | 0.140 |
Why?
|
| Transducers, Pressure | 1 | 2017 | 11 | 0.140 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 123 | 0.140 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 191 | 0.140 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 106 | 0.140 |
Why?
|
| Allergens | 4 | 2022 | 279 | 0.140 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 66 | 0.140 |
Why?
|
| Algorithms | 3 | 2021 | 1730 | 0.140 |
Why?
|
| HIV-1 | 1 | 2021 | 488 | 0.140 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 158 | 0.140 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 466 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 908 | 0.140 |
Why?
|
| Poverty | 1 | 2021 | 437 | 0.140 |
Why?
|
| Curriculum | 2 | 2014 | 768 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2020 | 295 | 0.140 |
Why?
|
| Pneumonia | 1 | 2021 | 341 | 0.140 |
Why?
|
| Pressure Ulcer | 1 | 2017 | 79 | 0.130 |
Why?
|
| Hyperkalemia | 1 | 2018 | 71 | 0.130 |
Why?
|
| Reproductive History | 1 | 2017 | 10 | 0.130 |
Why?
|
| Cancer Survivors | 1 | 2020 | 251 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 460 | 0.130 |
Why?
|
| Group Processes | 1 | 2017 | 52 | 0.130 |
Why?
|
| Menstruation | 1 | 2017 | 31 | 0.130 |
Why?
|
| Immunoglobulin E | 3 | 2023 | 171 | 0.130 |
Why?
|
| Obesity | 3 | 2018 | 2437 | 0.130 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 1692 | 0.130 |
Why?
|
| Pain Management | 1 | 2019 | 202 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2021 | 519 | 0.130 |
Why?
|
| Hypersensitivity | 1 | 2019 | 195 | 0.130 |
Why?
|
| Genotype | 3 | 2018 | 2719 | 0.130 |
Why?
|
| Aggression | 1 | 2018 | 232 | 0.130 |
Why?
|
| Biomarkers | 3 | 2021 | 3411 | 0.130 |
Why?
|
| Organizational Culture | 1 | 2017 | 105 | 0.130 |
Why?
|
| Minnesota | 1 | 2016 | 181 | 0.120 |
Why?
|
| Hypertension | 1 | 2025 | 1402 | 0.120 |
Why?
|
| Cause of Death | 1 | 2018 | 504 | 0.120 |
Why?
|
| Ovarian Reserve | 1 | 2015 | 11 | 0.120 |
Why?
|
| Calcium Carbonate | 1 | 2015 | 11 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2024 | 1660 | 0.120 |
Why?
|
| Trinucleotide Repeats | 1 | 2015 | 109 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1351 | 0.120 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2015 | 43 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 130 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2021 | 1411 | 0.110 |
Why?
|
| Food Hypersensitivity | 1 | 2018 | 167 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2017 | 395 | 0.110 |
Why?
|
| Insulin Resistance | 2 | 2018 | 700 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 489 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 64 | 0.110 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2015 | 126 | 0.110 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 75 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 276 | 0.110 |
Why?
|
| Acute Disease | 1 | 2017 | 1182 | 0.110 |
Why?
|
| Nursing Homes | 1 | 2015 | 107 | 0.110 |
Why?
|
| Body Composition | 2 | 2016 | 563 | 0.110 |
Why?
|
| Medicare | 1 | 2018 | 468 | 0.110 |
Why?
|
| Medicine in Literature | 1 | 2014 | 3 | 0.110 |
Why?
|
| Motion Pictures | 1 | 2014 | 6 | 0.110 |
Why?
|
| Museums | 1 | 2014 | 3 | 0.110 |
Why?
|
| Administration, Oral | 3 | 2022 | 718 | 0.110 |
Why?
|
| Multimedia | 1 | 2014 | 12 | 0.110 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2017 | 336 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 468 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2021 | 1139 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2018 | 386 | 0.110 |
Why?
|
| Young Adult | 8 | 2023 | 9921 | 0.110 |
Why?
|
| Alcoholic Beverages | 1 | 2013 | 18 | 0.100 |
Why?
|
| Cross Infection | 1 | 2017 | 344 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 906 | 0.100 |
Why?
|
| Textbooks as Topic | 1 | 2013 | 8 | 0.100 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 669 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2017 | 566 | 0.100 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2013 | 36 | 0.100 |
Why?
|
| Food Preferences | 1 | 2013 | 118 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 483 | 0.100 |
Why?
|
| Single-Blind Method | 3 | 2021 | 250 | 0.100 |
Why?
|
| Insulin | 1 | 2018 | 1244 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2017 | 578 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 100 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 591 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 822 | 0.100 |
Why?
|
| History of Medicine | 1 | 2012 | 5 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2024 | 3715 | 0.090 |
Why?
|
| Self Concept | 1 | 2013 | 164 | 0.090 |
Why?
|
| Europe | 1 | 2013 | 373 | 0.090 |
Why?
|
| Virus Shedding | 2 | 2021 | 82 | 0.090 |
Why?
|
| Heart Defects, Congenital | 1 | 2023 | 1887 | 0.090 |
Why?
|
| Child | 6 | 2023 | 25847 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5435 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2015 | 494 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 781 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2016 | 604 | 0.080 |
Why?
|
| Drug-Eluting Stents | 2 | 2025 | 70 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2013 | 201 | 0.080 |
Why?
|
| Injections, Subcutaneous | 2 | 2021 | 131 | 0.080 |
Why?
|
| Data Collection | 1 | 2012 | 395 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 782 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 1036 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2018 | 1583 | 0.080 |
Why?
|
| Heart Failure | 1 | 2023 | 2428 | 0.080 |
Why?
|
| Age Factors | 4 | 2018 | 2954 | 0.080 |
Why?
|
| Animals | 3 | 2020 | 36184 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1914 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1837 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 760 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 567 | 0.070 |
Why?
|
| Quality of Life | 2 | 2022 | 2160 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 3359 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 2286 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 3087 | 0.070 |
Why?
|
| Time Factors | 4 | 2021 | 6541 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 1136 | 0.070 |
Why?
|
| Pediatrics | 1 | 2016 | 1220 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 3043 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1419 | 0.060 |
Why?
|
| SEER Program | 2 | 2018 | 222 | 0.060 |
Why?
|
| Survival Rate | 2 | 2021 | 2204 | 0.060 |
Why?
|
| Prognosis | 3 | 2021 | 5032 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2017 | 3169 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 3735 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2025 | 115 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2025 | 804 | 0.050 |
Why?
|
| Tetraspanin 30 | 1 | 2023 | 2 | 0.050 |
Why?
|
| Avidin | 1 | 2023 | 19 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2024 | 120 | 0.050 |
Why?
|
| Basophils | 1 | 2023 | 11 | 0.050 |
Why?
|
| Leukotriene B4 | 1 | 2023 | 7 | 0.050 |
Why?
|
| Fatigue | 2 | 2015 | 199 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 540 | 0.050 |
Why?
|
| Neoplasms | 1 | 2018 | 2984 | 0.050 |
Why?
|
| Sirolimus | 1 | 2025 | 239 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1462 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 1363 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2023 | 87 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2016 | 1253 | 0.050 |
Why?
|
| Emotions | 2 | 2015 | 366 | 0.050 |
Why?
|
| San Francisco | 1 | 2021 | 20 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2025 | 410 | 0.050 |
Why?
|
| Angina Pectoris | 1 | 2022 | 68 | 0.050 |
Why?
|
| Exercise Test | 1 | 2023 | 263 | 0.050 |
Why?
|
| Dideoxynucleosides | 1 | 2021 | 10 | 0.050 |
Why?
|
| Lamivudine | 1 | 2021 | 27 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2021 | 37 | 0.050 |
Why?
|
| Tenofovir | 1 | 2021 | 23 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 297 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2023 | 814 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 186 | 0.040 |
Why?
|
| Dietary Supplements | 2 | 2015 | 487 | 0.040 |
Why?
|
| Canada | 1 | 2022 | 343 | 0.040 |
Why?
|
| Carbon Monoxide | 1 | 2021 | 26 | 0.040 |
Why?
|
| Clinical Chemistry Tests | 1 | 2020 | 5 | 0.040 |
Why?
|
| Ozone | 1 | 2021 | 20 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 30 | 0.040 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2020 | 48 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2023 | 185 | 0.040 |
Why?
|
| Operative Time | 1 | 2021 | 189 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2021 | 147 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2020 | 103 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2021 | 282 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2020 | 115 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2021 | 80 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 241 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 294 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 362 | 0.040 |
Why?
|
| Calcium | 2 | 2015 | 1104 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 453 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 823 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2021 | 188 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2020 | 272 | 0.040 |
Why?
|
| Remission Induction | 1 | 2020 | 307 | 0.040 |
Why?
|
| Urban Population | 1 | 2021 | 242 | 0.040 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2019 | 2 | 0.040 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2019 | 5 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2021 | 562 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 2019 | 13 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2023 | 519 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 789 | 0.040 |
Why?
|
| Confidentiality | 1 | 2019 | 106 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2025 | 700 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 151 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2019 | 37 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 3408 | 0.040 |
Why?
|
| Creatinine | 1 | 2020 | 416 | 0.040 |
Why?
|
| Veterans Health | 1 | 2020 | 180 | 0.040 |
Why?
|
| Acute Lung Injury | 1 | 2019 | 68 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 536 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2021 | 390 | 0.040 |
Why?
|
| Education | 1 | 2019 | 111 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2018 | 105 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 856 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 357 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2018 | 42 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 343 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 501 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2023 | 629 | 0.030 |
Why?
|
| Food | 1 | 2018 | 138 | 0.030 |
Why?
|
| Reference Standards | 1 | 2018 | 245 | 0.030 |
Why?
|
| Air Pollutants | 1 | 2019 | 115 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 145 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 132 | 0.030 |
Why?
|
| Interferons | 1 | 2018 | 144 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2023 | 8627 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 88 | 0.030 |
Why?
|
| Menarche | 1 | 2017 | 36 | 0.030 |
Why?
|
| Health Status | 1 | 2019 | 414 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 887 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 593 | 0.030 |
Why?
|
| Mortality | 1 | 2018 | 260 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 212 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2016 | 66 | 0.030 |
Why?
|
| Genes, Modifier | 1 | 2016 | 16 | 0.030 |
Why?
|
| Lovastatin | 1 | 2016 | 23 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2018 | 272 | 0.030 |
Why?
|
| Publication Bias | 1 | 2016 | 17 | 0.030 |
Why?
|
| Sunlight | 1 | 2016 | 26 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2016 | 50 | 0.030 |
Why?
|
| RNA, Untranslated | 1 | 2016 | 120 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 719 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 1392 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 604 | 0.030 |
Why?
|
| Simvastatin | 1 | 2016 | 77 | 0.030 |
Why?
|
| Hot Flashes | 1 | 2015 | 7 | 0.030 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2017 | 178 | 0.030 |
Why?
|
| Stents | 1 | 2021 | 880 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1204 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 256 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2016 | 149 | 0.030 |
Why?
|
| Energy Intake | 1 | 2018 | 515 | 0.030 |
Why?
|
| Maternal Age | 1 | 2015 | 141 | 0.030 |
Why?
|
| Receptors, Nicotinic | 1 | 2016 | 139 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2020 | 750 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2022 | 2026 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 314 | 0.030 |
Why?
|
| Graft Survival | 1 | 2017 | 482 | 0.030 |
Why?
|
| Indoles | 1 | 2016 | 202 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 306 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 195 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 781 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 480 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 552 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2016 | 236 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1310 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 674 | 0.030 |
Why?
|
| Family Therapy | 1 | 2013 | 35 | 0.030 |
Why?
|
| Skin | 1 | 2016 | 542 | 0.030 |
Why?
|
| Acetaminophen | 1 | 2014 | 101 | 0.030 |
Why?
|
| School Health Services | 1 | 2013 | 102 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2013 | 206 | 0.020 |
Why?
|
| Proteomics | 1 | 2016 | 602 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 151 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 835 | 0.020 |
Why?
|
| Infant | 2 | 2018 | 13235 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2018 | 14865 | 0.020 |
Why?
|
| Counseling | 1 | 2013 | 240 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 1694 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2016 | 815 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 4574 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 528 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 683 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2013 | 509 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 2242 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 1151 | 0.020 |
Why?
|
| Adolescent | 2 | 2018 | 20549 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 1388 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 1677 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2013 | 726 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2854 | 0.020 |
Why?
|
| Diet | 1 | 2013 | 1170 | 0.020 |
Why?
|